Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Net Income (2016 - 2025)

Lisata Therapeutics' Net Income history spans 11 years, with the latest figure at -$3.0 million for Q4 2025.

  • For Q4 2025, Net Income rose 35.92% year-over-year to -$3.0 million; the TTM value through Dec 2025 reached -$16.6 million, up 17.01%, while the annual FY2025 figure was -$16.6 million, 17.01% up from the prior year.
  • Net Income reached -$3.0 million in Q4 2025 per LSTA's latest filing, up from -$4.2 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$3.0 million in Q4 2025 to a low of -$6.2 million in Q1 2023.
  • Average Net Income over 3 years is -$4.8 million, with a median of -$4.8 million recorded in 2024.
  • Peak YoY movement for Net Income: dropped 25.25% in 2024, then surged 35.92% in 2025.
  • A 3-year view of Net Income shows it stood at -$5.4 million in 2023, then grew by 14.07% to -$4.6 million in 2024, then soared by 35.92% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Net Income are -$3.0 million (Q4 2025), -$4.2 million (Q3 2025), and -$4.7 million (Q2 2025).